1986
DOI: 10.1093/clinids/8.supplement_4.s439
|View full text |Cite
|
Sign up to set email alerts
|

Passive Immunotherapy for Encephalitis Caused by Herpes Simplex Virus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
9
0
1

Year Published

1987
1987
2014
2014

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 24 publications
(12 citation statements)
references
References 23 publications
2
9
0
1
Order By: Relevance
“…Although it is well-established that Abs prevent infection with several viruses, including varicella-zoster [37], hepatitis B [38], HTLV-I [39], and HIV-1 [40][41][42], the role of Abs in controlling established virus infections is much more controversial. Passive administration of various immunoglobulin preparations has been used effectively to treat infections with a variety of viruses, such as echovirus, respiratory syncytial virus, and herpes simplex [43][44][45]. To date, however, data suggesting that Abs can control established HIV-1 infection are controversial.…”
Section: Discussionmentioning
confidence: 99%
“…Although it is well-established that Abs prevent infection with several viruses, including varicella-zoster [37], hepatitis B [38], HTLV-I [39], and HIV-1 [40][41][42], the role of Abs in controlling established virus infections is much more controversial. Passive administration of various immunoglobulin preparations has been used effectively to treat infections with a variety of viruses, such as echovirus, respiratory syncytial virus, and herpes simplex [43][44][45]. To date, however, data suggesting that Abs can control established HIV-1 infection are controversial.…”
Section: Discussionmentioning
confidence: 99%
“…IVIG is able not only to neutralize any extracellular virus but also to help destroy cells acutely infected with HSV1 [Kohl and Loo, 1986]: a useful feature as the virus can be transferred from cell to cell without release of extracellular virus. In murine models of HSE, IVIG was found to protect against death and it reduced the number of trigeminal ganglia containing latent HSV1 [Erlich and Mills, 1986]. Further, a study of genital herpes in humans showed that the reduction in recurrence frequency and duration was far greater, and the lesion severity less, with IVIG treatment than with ACV, and there was a trend towards IVIG causing a greater reduction in viral load [Masci et al 1995].…”
Section: Antiviral Treatment For Ad?mentioning
confidence: 99%
“…Não obstante, esse experimento demonstrou que os anticorpos administrados pela via IP são eficientemente absorvidos e atingem níveis séricos consideráveis em um curto intervalo de tempo. Com isso, esse protocolo pode ser utilizado para avaliar o efeito da imunidade passiva na prevenção e/ou tratamento da infecção neurológica, a exemplo do que tem sido realizado na doença neurológica experimental pelo HSV-1 em camundongos (Erlich & Mills 1986). …”
Section: Imunidade Passiva E Proteçãounclassified